Saturday 17 October 2026
Export EXOZ’s income statement to Excel — free account
eXoZymes Inc.
EXOZ Healthcare Biotechnology
eXoZymes Inc.’s revenue for fiscal 2023 (year ended December 2023) was $70,100.00. In the quarter to June 2026, EPS fell 17.9%, free cash flow fell 3.25% and total debt fell 52.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.09
0.09
+2.25%
Follow EXOZ
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 8.50 | 8.86 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 23.00 | 23.99 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 31 | 32 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | — | — | |||||
| EBT | — | — | — | — | — | — | — | (2) | (6) | (9) | |||||
| EBT margin, % | — | — | — | — | — | — | — | (2,847.50) | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | (2) | (6) | (9) | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.01 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | (0.33) | (0.89) | (1.09) | |||||
| Cash flow | — | — | — | — | — | — | — | (0.19) | (1.30) | (0.78) | |||||
| Capex | — | — | — | — | — | — | — | (0.05) | (0.06) | (0.02) | |||||
| Free cash flow | — | — | — | — | — | — | — | (0.24) | (1.36) | (0.80) | |||||
| Book value | — | — | — | — | — | — | — | (0.06) | 1.59 | 0.41 | |||||
| Shares, m | — | — | — | — | — | — | — | 6 | 7 | 8 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | — | — | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | (14.77) | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (1) | (9) | (7) | ||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | (1) | (9) | (7) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (1) | 9 | 2 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | 0 | |||||
| Net debt | — | — | — | — | — | — | — | 0 | (10) | (3) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | 0 | 10 | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (70.65) | (96.38) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (528.52) | (1,438.03) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (116.80) | (132.56) | |||||
Negative figures in brackets.
Fiscal years to Dec 2023
Charts ten years each
eXoZymes Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LBPS 4D pharma PLC Sponsored ADR | $37.2M | — (loss-making) | — | +41.64% (above 0%: growing) | n/m | −16,367.69% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| EXOZ eXoZymes Inc. | $37.1M | — (loss-making) | — | — | n/m | −3.25% (below 0%: shrinking) | — | 0.00% | |
| FLNA Cassava Sciences, Inc. | $36.8M | — (loss-making) | — | +1,328.04% (above 0%: growing) | n/m | +21.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LITS Lite Strategy, Inc. | $36.3M | — (loss-making) | — (loss-making) | +647.96% (above 0%: growing) | n/m | +179.28% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EDSA Edesa Biotech, Inc. | $36.1M | — (loss-making) | — (loss-making) | −99.88% (below 0%: shrinking) | n/m | −81.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NNVC NanoViricides, Inc. | $35.0M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CRVO CervoMed Inc. | $34.0M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IRLA Quince Therapeutics, Inc. | $33.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $35.5M | — | — | +41.64% | — | −15.07% | 0.00% | 0.00% |
eXoZymes Inc. (EXOZ) key facts
- Concern: eXoZymes Inc. reported a net loss of $9.2 million, or a loss of $1.09 per share, for fiscal 2025.
- eXoZymes Inc. (EXOZ) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- eXoZymes Inc.’s revenue for fiscal 2023 (year ended December 2023) was $70,100.00.
- As of October 16, 2026, EXOZ traded at $4.09, a market capitalization of $37.1 million.
- Return on equity was −132.6% and debt-to-equity 0.01.
eXoZymes Inc. (EXOZ) Latest News
No news at this impact. Lower the threshold for more.